Under the Paperwork Reduction Act of 1995, no persons are requ

F A E

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor COS		GROVE, Daniel J.
Art Unit		
Examiner Name		
Attamen Dealest Numb		DOZENJURNA DIJI 4000

	U.S.PATENTS Remove								_		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue [Name of Patentee or Applicant of cited Document		Pages,Columns,Lines who Relevant Passages or Rel Figures Appear				
	1										
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	of cited Decument		Relev	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1										
If you wis	h to a	dd additional U.S. Publi		p		, , , , , , , , , , , , , , , , , , , ,		d buttor			
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patentee Applicant of cited Document	e or	Pages,Colu where Relev Passages o Figures App	vant r Relevant	T5
	1										
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials*	Cite No	Include name of the au (book, magazine, journ publisher, city and/or of	nal, seri	al, symp	osium,	catalog, etc), o					Тs

	1	Bollard IllMonsato Company, "Bacillus Thuringiensis Cry2Ab2 protein and the Genetic Material Necessary for Its Production in Colton (000467) Fact Sheef* www.epa.gov/lopphppdf/libopesticides/ingredients/factsheet/of factsheet_006487.html U.S. Environmental Protection Agency, Pesticides: Regulating Pesticides, 12/23/2002 pp 1-19	
	2	Frutos, Roger et al. "Managing Insect Resistance to Plants Producing Bacillus thuring ensis Toxins" Critical Reviews in Biotechnology, 19(3):227-276 (1999)	
	3	Roush, R.T. "Two-toxin strategies for management of insecticidal transgenic crops: can pyramiding succeed where pestidide motuure have not?" 1998 The Royal Society, Phil. Trans. R. Soc. Lond. 8 (1996) 353 pp. 1777-1786.	
	4	Siqueira, Herbert A. A., et al. "Cross-Resistance of Cryf Ab-Selected Ostrinia nubitalis (Lepidoptera: Crambidae) to Bacillus thuringienss 6-Endotoxns' 2004 Journal of Economic Entomology, Vol. 97, No. 3, pp. 1049-1057	
	5	Tabashnik, Bruce E "Delaying insect adaptation to transgeric plants: Seed Mixtures and Retugia Reconsidered." (Record 1 of 5 in Biological Abstracts); Proceedings of the Royal Society of London Series B Biological Sciences. 1994; 235 (13/2) 7-12 - 1 page	
	6	Parker, C. D. Jr. et al. "Interplant movement of Heliothis virescens (Lepidopteria: Noctudae) larvae in pure and mixed plantings of cotton with and without expression of the Cryf Ac delta-endotoxin protein of Bacillus thuringlensis Berlinger" (Record 2 of 5 in Biological Abstracts). Journal of Economic Entomology, Aug., 1999; 92(4): 837-845. 1 page	
	7	Ramachandran-Suresh et al. "Intraspecific competition of an insect-resistant transgenic canola in seed mixtures" (Record 3 of 5 in Biological Abstracts) Agronomy Journal March-April 2000; 92(2): 389-374. 1 page	
	8	Conner, A.J., et al "Plant breeding and seed marketing options for the introduction of transgeric insect-resistant crops" (Record 4 of 5 in CAB Abstacts) Proceedings of OECD workshop on Ecological implications of Transgeric crops containing Bit study genes, let in New Zealand on 10-14 January 1994. Biocontrol Science and Technology 1994; 4: 4, 463-473, 52 ref., 1 page	
	9	Ferro, David N "Potential for resistance to Bacillus thuringiensis: Colorado potato beetle (Coleoptera Chrysomeldae): A model system" (Record 5 of 5 in Biological Abstracts) American Entomologist 1993, 39(1) 38-44. 1 page	
	10	Whaton, M.E. et al. "Bacius thuringiensis: Use and Resistance Management", "In Inssecticides with novel modes of action: mechanism and application", Ishaaya, I. and Deghelle, D., Eds., Springer, Berlin, Chapter 7, pp 106-137 (1998)	
If you wis	h to a	d additional non-patent literature document citation information please click the Add button Add	

	Application Number		
NEODWATION DIGGI COURT	Filing Date		
NFORMATION DISCLOSURE	First Named Inventor	COSGROVE, Daniel J.	
Not for submission under 37 CFR 1.99)	Art Unit		
······	Examiner Name		
	Attorney Docket Numb	er	P07504US01 - PHI 1883

EXAMINER SIGNATURE					
Examiner Signature		Date Considered			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a					

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

16c Kinc Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 801.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST3.) 3 "For implement perfect outcomests, the enclosion of the year of the register or impressed the sent and the platent document. 4 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST1.6 if possible, "Applicant is to place a check mark here if English languages the resistance in statistics."

Application Number Fling Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number | COSGROVE, Daniel J. Art Unit Examiner Name | Attorney Docket Number | P07504US01 - PH 1883

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication of form a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, to fixe for information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/3/(k).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

offit of the signature.						
Signature	/HEIDI S. NEBEL/	Date (YYYY-MM-DD)	2006-09-25			
Name/Print	HEIDI S. NEBEL	Registration Number	37,719			

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to life (and by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, u.S. Operatment of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to a patient application or patient. If you do not furnish the requested the process another examine your submission, which may visually intermediate or of redesting to a submission or the basic log process another examine; your submission, which may visually intermediate or of redesting to a submission or the submission or the submission of the submission or the submission of the submission of the submission or the submission of the submission or the submission of the submission or the submission or the submission of the submission or the submission or the submission or the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.